Therapeutic Advances in Metastatic Melanoma: TILs, ImmTACs, and Targeted Therapies

Read full text Summarise with VIRAT
Authors: Alexandra Haugh, Krista M. Rubin
Cited by: 0
References: 3

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Therapeutic options for metastatic melanoma have expanded dramatically over the past decade. Advances in tumor biology, immunotherapy, and adoptive cellular therapy are offering patients more options and requiring oncology advanced practitioners to develop familiarity with increasingly complex treatment modalities and care pathways. Speakers at JADPRO Live 2025 focused on extracutaneous melanoma—particularly mucosal and uveal melanoma—and highlighted novel immune-based therapies, including immune-mobilizing monoclonal T-cell receptors against cancer (ImmTACs) and tumor-infiltrating lymphocyte (TIL) therapy.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Cutaneous Melanoma Detection and Management Immunotherapy and Immune Responses

Publication details

Journal / source
Journal of the Advanced Practitioner in Oncology
Volume
17
Issue
2
Publication date
27 February 2026
Language
EN